1
|
Liu WY, Liu H, Aggarwal J, Huang ZL, Horner RL. Differential activating effects of thyrotropin-releasing hormone and its analog taltirelin on motor output to the tongue musculature in vivo. Sleep 2021; 43:5813557. [PMID: 32227104 PMCID: PMC7487885 DOI: 10.1093/sleep/zsaa053] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Revised: 02/12/2020] [Indexed: 02/06/2023] Open
Abstract
Thyrotropin-releasing hormone (TRH) is produced by the hypothalamus but most brain TRH is located elsewhere where it acts as a neuromodulator. TRH-positive neurons project to the hypoglossal motoneuron pool where TRH receptor RNA shows a high degree of differential expression compared with the rest of the brain. Strategies to modulate hypoglossal motor activity are of physiological and clinical interest given the potential for pharmacotherapy for obstructive sleep apnea (OSA), a common and serious respiratory disorder. Here, we identified the effects on tongue motor activity of TRH and a specific analog (taltirelin) applied locally to the hypoglossal motoneuron pool and systemically in vivo. Studies were performed under isoflurane anesthesia and across sleep–wake states in rats. In anesthetized rats, microperfusion of TRH (n = 8) or taltirelin (n = 9) into the hypoglossal motoneuron pool caused dose-dependent increases in tonic and phasic tongue motor activity (both p < 0.001). However, the motor responses to TRH were biphasic, being significantly larger “early” in the response versus at the end of the intervention (p ≤ 0.022). In contrast, responses to taltirelin were similar “early” versus “late” (p ≥ 0.107); i.e. once elicited, the motor responses to taltirelin were sustained and maintained. In freely behaving conscious rats (n = 10), microperfusion of 10 μM taltirelin into the hypoglossal motoneuron pool increased tonic and phasic tongue motor activity in non-rapid-eye-movement (REM) sleep (p ≤ 0.038). Intraperitoneal injection of taltirelin (1 mg/kg, n = 16 rats) also increased tonic tongue motor activity across sleep–wake states (p = 0.010). These findings inform the studies in humans to identify the potential beneficial effects of taltirelin for breathing during sleep and OSA.
Collapse
Affiliation(s)
- Wen-Ying Liu
- State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Department of Pharmacology, Institute of Brain Science, School of Basic Medical Science, Fudan University, Shanghai, China.,Institute of Medical Science, University of Toronto, Toronto, ON, Canada
| | - Hattie Liu
- Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Jasmin Aggarwal
- Department of Physiology, University of Toronto, Toronto, ON, Canada
| | - Zhi-Li Huang
- State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Department of Pharmacology, Institute of Brain Science, School of Basic Medical Science, Fudan University, Shanghai, China
| | - Richard L Horner
- Institute of Medical Science, University of Toronto, Toronto, ON, Canada.,Department of Medicine, University of Toronto, Toronto, ON, Canada.,Department of Physiology, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
2
|
Asai H, Watanabe Y, Yamauchi-Kohno R, Doi O. Reversal of hemorrhagic shock in rats using the metabolically stable thyrotropin-releasing hormone analog taltirelin hydrate. J Recept Signal Transduct Res 2011; 31:416-22. [DOI: 10.3109/10799893.2011.625427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
3
|
Kinoshita K, Yamamura M, Sugihara J, Suzuki M, Matsuoka Y. Taltirelin Hydrate (TA-0910): An Orally Active Thyrotropin-Releasing Hormone Mimetic Agent with Multiple Actions. CNS DRUG REVIEWS 2006. [DOI: 10.1111/j.1527-3458.1998.tb00039.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
Santucci AC, Perez S. Multiple injections of thyrotropin releasing hormone fail to reverse learning and memory deficits in rats with lesions of the nucleus basalis of meynert. Behav Brain Res 2002; 136:433-8. [PMID: 12429405 DOI: 10.1016/s0166-4328(02)00195-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The learning and memory enhancing effects of thyrotropin releasing hormone (TRH) was examined in an animal model of Alzheimer's disease. Adult rats were prepared with either sham surgeries or cholinergic lesions of the nucleus basalis of Meynert (nbM). Subjects were injected (ip) with one of three doses of TRH (0, 5, 10 mg/kg) starting on the day of surgery and continuing once every other day for a total of four injections. Performance (four trials/day for 4 days, 30 m inter-trial interval) in a Morris water maze was assessed one week after the last TRH injection (i.e., 2 weeks postoperatively). Latency to find the hidden platform served as the dependent variable. Results indicated that damage to the nbM impaired task performance in that animals with nbM lesions generally required more time to find the platform and showed less trial-to-trial improvement. Treatment with TRH failed to reverse this lesion-induced deficit. These results suggest that multiple injections of TRH do not provide residual protection against the deleterious effects on learning and memory produced by cholinergic lesions of the basal forebrain. Other doses and administration parameters, however, need to be studied in order to determine the generalizability of these findings.
Collapse
Affiliation(s)
- Anthony C Santucci
- Deptartment of Psychology, Manhattanville College, 2900 Purchase Street, Purchase, NY 10577, USA.
| | | |
Collapse
|
5
|
Martinez R, Molchan SE, Lawlor BA, Thompson K, Martinson H, Latham G, Weingartner H, Sunderland T. Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans. Biol Psychiatry 1997; 41:50-7. [PMID: 8988795 DOI: 10.1016/0006-3223(95)00674-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The central anticholinergic drug scopolamine has been used to model aspects of the memory impairment that occurs in Alzheimer's disease and in aging. To determine whether nonspecific stimulant effects can attenuate the cognitive impairment induced by scopolamine, we studied the effects of scopolamine and the stimulant dextroamphetamine in 17 young normal volunteers. After a baseline day of cognitive testing, subjects participated in two study days, in which they received dextroamphetamine (d-AMP) (0.25 mg/kg p.o.) + scopolamine (0.5 mg i.v.) and placebo + scopolamine, in randomized order under double-blind conditions. There were no statistically significant differences in cognitive test performance between the two drug conditions with the exception of one of the category retrieval tasks. Stimulant effects were documented to occur by other measures. We conclude that d-AMP at the dose used does not attenuate the memory impairment induced by scopolamine.
Collapse
Affiliation(s)
- R Martinez
- Section on Geriatric Psychopharmacology, National Institute of Mental Health, Bethesda, Maryland, USA
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Shinoda M, Matsuo A, Toide K. Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion. Eur J Pharmacol 1996; 305:31-8. [PMID: 8813528 DOI: 10.1016/0014-2999(96)00173-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We studied behavioral and pharmacological effects of a novel prolyl endopeptidase inhibitor, (S)-2-[[(S)-2-(hydroxyacetyl)- 1-pyrrolidinyl]carbonyl]-N-(phenylmethyl)-1-pyrrolidine-car boxamide (JTP-4819), in rats with middle cerebral artery occlusion. Administration of JTP-4819 (0.1 and 1 mg/kg p.o for 7 days) significantly prolonged passive avoidance latency, while the latency of rats with middle cerebral artery occlusion receiving the vehicle was significantly shorter than that of sham-operated rats. The prolonged escape latency in the Morris water maze task in rats with middle cerebral artery occlusion was also significantly reduced by administration of JTP-4819 (0.3 and 1 mg/kg p.o.). Interestingly, administration of JTP-4819 (0.3-3 mg/kg p.o. for 15 days) restored the decreased cortical thyrotropin-releasing hormone (TRH)-like immunoreactivity content of rats with middle cerebral artery occlusion but did not affect the cortical and hippocampal substance P- or arginine vasopressin-like immunoreactivity content. These results suggest that JTP-4819 ameliorates memory impairment due to middle cerebral artery occlusion by restoring the cortical TRH content.
Collapse
Affiliation(s)
- M Shinoda
- Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan
| | | | | |
Collapse
|
7
|
Lexow N, Joyce JN, Kim SJ, Phillips J, Casanova MF, Bird ED, Kleinman JE, Winokur A. Alterations in TRH receptors in temporal lobe of schizophrenics: a quantitative autoradiographic study. Synapse 1994; 18:315-27. [PMID: 7886624 DOI: 10.1002/syn.890180407] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
We utilized quantitative autoradiography to determine the distribution of receptors for thyrotropin-releasing hormone (TRH) throughout the human temporal lobe and to examine the distribution of these receptors in discrete subregions of the temporal lobe from patients diagnosed premortem with schizophrenia. When compared to non-neurologic controls, schizophrenic patients demonstrated an increase of 51% in the concentration of TRH receptors in the molecular layer of the dentate gyrus. Within nuclei of the schizophrenic amygdala, marked decreases were found in the central (44%), medial (38%), cortical (36%), accessory cortical (52%), lateral (54%), and medial basal (22%) nuclei. We also examined postmortem brain samples from patients with Huntington's disease, amyotrophic lateral sclerosis, and Alzheimer's disease for alterations in the distribution of TRH receptors. No significant differences from non-neuropsychiatric controls were noted within the hippocampus in any of these disease states; however, slight alterations were noted in the central and medial basal amygdala in Huntington's disease and in the cortical amygdala in Alzheimer's disease. These disease-specific findings suggest that TRH may play a role in the neurochemical dysfunction of schizophrenia.
Collapse
Affiliation(s)
- N Lexow
- Department of Psychiatry, University of Pennsylvania, Philadelphia 19104
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Watson CD, Hewitt MJ, Fone KC, Dickinson SL, Bennett GW. Behavioural effects of scopolamine and the TRH analogue RX77368 on radial arm maze performance in the rat. J Psychopharmacol 1994; 8:88-93. [PMID: 22298534 DOI: 10.1177/026988119400800203] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Effects of repeated intracerebroventricular administration of the thyrotrophin-releasing hormone (TRH) analogue, RX77368 (3,3'-dimethyl-TRH, 2 μg, once daily), on a scopolamine-induced performance deficit in an eight-arm radial maze were evaluated in adult rats. Scopolamine (0.3 mg/kg i.p.-30 min) pre-treatment produced a significant deficit in the number of unrepeated arm entries and total arm entries and increased the percentage of incorrect arm entries and the total time on the maze, compared with saline-treated controls. Prior treatment with RX77368 (40 min before maze testing) produced a partial but significant attenuation of the scopolamine-induced performance deficit on the maze during the first five trials but RX77368 also enhanced maze performance during the same period when given alone. These results suggest that the observed scopolamine-induced performance deficit on the radial arm maze partly results from a reduction in locomotion and maze exploration rather than solely impairment of memory, and that RX77368 treatment may improve radial maze performance by increasing arousal and exploratory behaviour in rats rather than directly enhancing cognition.
Collapse
Affiliation(s)
- C D Watson
- Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham University, Nottingham NG7 2UH
| | | | | | | | | |
Collapse
|
9
|
POSTER COMMUNICATIONS. Br J Pharmacol 1993; 110:81P-184P. [DOI: 10.1111/j.1476-5381.1993.tb16292.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
10
|
Aspley S, Fone KC. Galanin fails to alter both acquisition of a two trial per day water maze task and neurochemical markers of cholinergic or serotonergic neurones in adult rats. Brain Res 1993; 622:330-6. [PMID: 7694768 DOI: 10.1016/0006-8993(93)90840-j] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The co-existence of galanin with acetylcholine in ventral forebrain neurones combined with evidence that galanin attenuates cholinergic function and is present in senile plaques in Alzheimer's disease all implicate this neuropeptide in the regulation of cognition. This study simultaneously examines the effect of galanin on acquisition in a Morris water maze and post-training markers of cholinergic and serotonergic forebrain neurones thought to be involved in cognition. Synthetic porcine galanin (10(-9) to 10(-6) M) produced dose-related inhibition of atropine sensitive indirectly-evoked contractions of an isolated guinea-pig ileum which was unaffected by naloxone (10(-7) M). This confirmed the bioactivity of synthetic galanin, which reduces acetylcholine, but not opiate, release from the ileal myenteric plexus. Galanin pretreatment (1 or 10 micrograms i.c.v., -15 min) failed to alter acquisition of a Morris water maze task (2 trials per day) in Hooded Lister rats. Following behavioural acquisition, five days of galanin administration did not alter choline acetyltransferase activity, thyrotrophin-releasing hormone-like immunoreactivity or 5-hydroxytryptamine levels or turnover in the frontal cortex, hippocampus or septum, although dopamine levels were significantly elevated in the frontal cortex. These findings suggest that galanin does not affect acquisition in a simple visual-spatial task which taxes reference more than working memory and questions the assumption that a cholinergic mechanism is the major contributor to previously reported cognitive effects of galanin.
Collapse
Affiliation(s)
- S Aspley
- Department of Physiology and Pharmacology, Queen's Medical Centre, Nottingham University, UK
| | | |
Collapse
|
11
|
Kasparov SA, Chizh BA. The NMDA-receptor antagonist dizocilpine (MK-801) suppresses the memory facilitatory action of thyrotropin-releasing hormone. Neuropeptides 1992; 23:87-92. [PMID: 1454156 DOI: 10.1016/0143-4179(92)90083-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Thyrotropin-releasing hormone (TRH) has been shown to improve memory both in animal amnesia models and in humans. In an earlier study we have found that respiratory stimulant action of TRH is mediated through the N-methyl-D-aspartate (NMDA) receptors. Since brain NMDA receptors are implicated in neuronal plasticity, we have investigated whether the non-competitive NMDA antagonist dizocilpine antagonizes the memory-facilitatory action of TRH. TRH (5 mg/kg i.p.) increased passive avoidance scores in the rats in both memory retention and retrieval tests. Dizocilpine (0.2 mg/kg i.p.) caused no significant performance changes. However, it completely blocked the improvement of retention caused by TRH and reversed its effect on retrieval. We conclude that the facilitatory effect of TRH on avoidance retention and retrieval may be mediated by NMDA receptors.
Collapse
Affiliation(s)
- S A Kasparov
- Department of Pharmacology, Moscow Sechenov Medical Academy, Russia
| | | |
Collapse
|
12
|
Molchan SE, Mellow AM, Hill JL, Weingartner H, Martinez R, Vitiello B, Sunderland T. The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers. J Psychopharmacol 1992; 6:489-500. [PMID: 22291397 DOI: 10.1177/026988119200600404] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Thyrotropin-releasing hormone (TRH), a neuromodulator and possibly a neurotransmitter in the central nervous system, was shown in a prior study of young normal volunteers to attenuate the memory impairment induced by the anticholinergic drug scopolamine. In the present study, the cognitive, behavioral and physiologic effects of high dose TRH (0.5 mg/kg), both alone and following administration of scopolamine, were examined in 10 Alzheimer's disease (AD) patients (mean age±SD=63.5 years) and 12 older normal volunteers (mean age=64.9±8.8 years). On the day AD subjects received TRH alone, modest but statistically significant improvement from baseline performance was documented on some tests of learning and memory, especially in those with mild dementia severity. In comparing cognitive test performance between the scopolamine alone and scopolamine+TRH conditions, only two test scores were significantly higher in the latter condition. In the group of older volunteers, TRH did not attenuate scopolamine-induced cognitive impairment, contrary to prior findings in a group of younger controls. In fact, older subjects performed worse after receiving scopolamine followed by TRH than after receiving scopolamine alone. In addition, no change from baseline cognitive performance was detected after subjects received TRH alone. These findings raise several questions and speculations on possible age-related changes in the cholinergic system, as well as on the mechanism of the interaction of TRH with the cholinergic system.
Collapse
Affiliation(s)
- S E Molchan
- Unit on Geriatric Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD
| | | | | | | | | | | | | |
Collapse
|